Research
Clinical trials
Every amyloidosis study now recruiting, about to open, or enrolling by invitation, anywhere in the world, listed straight from ClinicalTrials.gov and refreshed every day.
Information, not medical advice. The Alliance does not run these studies and cannot enrol you in one. If a trial looks relevant, discuss it with the doctor who follows your amyloidosis.

Recruiting and upcoming studies
The list covers AL, ATTR and AA amyloidosis as well as cerebral amyloid angiopathy. Each card says where the study stands: open to anyone who meets its criteria, not yet open, or restricted to people the investigators invite. Studies that close simply leave the list.
Showing 61–72 of 202 trials
Not yet recruitingATTR (transthyretin)
Right Ventricular Septal Biopsy to Detect Cardiac Amyloidosis (opens on ClinicalTrials.gov)
People eligible for this study have had the suggestion from their doctor to receive a cardiac pacemaker or defibrillator to treat a cardiac condition…
- Study
- Observational (registry, imaging)
- Sponsor
- Geisinger Clinic
No study locations listed yet
NCT07784712Updated 25 August 2026
RecruitingNot specified
Ultrasound Therapy In Cardiac Amyloidosis (opens on ClinicalTrials.gov)
This is a prospective pilot clinical study of subjects with cardiac amyloidosis and control subjects without amyloidosis where we plan to evaluate changes in…
- Study
- Interventional (treatment)
- Phase
- Phase 4
- Sponsor
- Brigham and Women's Hospital
Recruiting in: United States
NCT04667494Updated 21 August 2026
RecruitingNot specified
Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy (opens on ClinicalTrials.gov)
Recently, treatment with tafamidis in patients with cardiac ATTR lead to a significant reduction in mortality. The Perugini score is commonly used on planar…
- Study
- Interventional (treatment)
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Recruiting in: France
NCT04849754Updated 20 August 2026
RecruitingAL (light chain)
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis (opens on ClinicalTrials.gov)
This study will evaluate the safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis.
- Study
- Interventional (treatment)
- Phase
- Phase 1
- Sponsor
- Dana-Farber Cancer Institute
Recruiting in: United States
NCT06569147Updated 19 August 2026
RecruitingAL (light chain)
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis (opens on ClinicalTrials.gov)
The goal of this study is to test the safety of drug, Belantamab Mafodotin, and see what effects (good and bad) it has on…
- Study
- Interventional (treatment)
- Phase
- Phase 1
- Sponsor
- University of Texas Southwestern Medical Center
Recruiting in: United States
NCT05145816Updated 19 August 2026
RecruitingAL (light chain)
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) (opens on ClinicalTrials.gov)
This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned…
- Study
- Interventional (treatment)
- Phase
- Phase 1
- Sponsor
- Regeneron Pharmaceuticals
Recruiting in: GreeceSouth KoreaSpainTaiwan+2
NCT06292780Updated 18 August 2026
Enrolling by invitationNot specified
PET Imaging With [18F]Fluselenamyl in People With Cardiac Amyloidosis (opens on ClinicalTrials.gov)
This observational study will evaluate the imaging performance of the investigational positron emission tomography (PET) radiotracer[18F]Fluselenamyl (FSA) in individuals with cardiac amyloidosis. The study…
- Study
- Interventional (treatment)
- Phase
- Phase 1
- Sponsor
- Washington University School of Medicine
Recruiting in: United States
NCT07771621Updated 18 August 2026
Enrolling by invitationATTR (transthyretin)
Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (opens on ClinicalTrials.gov)
The TRACE-AI Diagnostic Study will evaluate the performance of artificial intelligence (AI) models applied to electrocardiograms (AI-ECG) and echocardiograms (AI-Echo) to identify transthyretin amyloid…
- Study
- Observational (registry, imaging)
- Sponsor
- Yale University
Recruiting in: United States
NCT07398950Updated 18 August 2026
Not yet recruitingAL (light chain)
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis (opens on ClinicalTrials.gov)
This Phase I study is designed to evaluate the safety and efficacy of FKC289 in subjects with relapsed/refractory primary light chain (AL) amyloidosis.The primary…
- Study
- Interventional (treatment)
- Phase
- Phase 1
- Sponsor
- Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Recruiting in: China
NCT07765524Updated 14 August 2026
RecruitingATTR (transthyretin)
Liver and Coagulation Disorders in Cardiac Transthyretin Amyloidosis (opens on ClinicalTrials.gov)
Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive infiltrative cardiomyopathy caused by the deposition of misfolded transthyretin protein within the myocardium. Current disease staging and…
- Study
- Observational (registry, imaging)
- Sponsor
- University of Messina
Recruiting in: Italy
NCT07766135Updated 14 August 2026
Not yet recruitingNot specified
Selinexor, Daratumumab, and Dexamethasone (XDd) for Light-Chain Cardiac Amyloidosis (opens on ClinicalTrials.gov)
The goal of this clinical trial is to evaluate whether selinexor combined with daratumumab and dexamethasone (XDd) can treat patients with advanced light-chain cardiac…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Beijing Anzhen Hospital
No study locations listed yet
NCT07743957Updated 13 August 2026
RecruitingATTR (transthyretin)
ATTR Cardiac Amyloidosis in a Selected Population (opens on ClinicalTrials.gov)
Patients operated for carpal tunnel syndrome (CTS) at Ålesund Hospital (200 patients) will have a biopsy to diagnose ATTR amyloidosis. Patients with positive biopsy…
- Study
- Observational (registry, imaging)
- Sponsor
- Helse Møre og Romsdal HF
Recruiting in: Norway
NCT06458374Updated 12 August 2026
This list only covers amyloidosis studies that are open or about to open. The registry holds every study, including those already completed.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). List last retrieved on 7 November 2026. clinicaltrials.gov
Not sure where to start?
Our member associations know the teams running these studies in their own country, and can help you prepare the conversation with your doctor.